cd8-pe clone sk1 antibody Search Results


cd8-pe clone sk1 antibody  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc cd8-pe clone sk1 antibody
(A) Differences in the proportions of monocytes, T cells and NK cells with age. (B) Differences with age in the % of T cells that are CD4+ and <t>CD8+,</t> in the CD4/CD8 ratio with age, in the proportion of T cells that are Tregs, and in the proportion of CD4 and CD8 cells that are CD28+ and -. (C) Anti-CD3 + anti-CD28 stimulated proliferation (left panel) and IFNγ production (right panel). Results are expressed as the mean ± SEM. * indicates a statistically significant difference (P <0.05) between the young and old cohorts.
Cd8 Pe Clone Sk1 Antibody, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd8-pe clone sk1 antibody/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
cd8-pe clone sk1 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Differences in the proportions of monocytes, T cells and NK cells with age. (B) Differences with age in the % of T cells that are CD4+ and CD8+, in the CD4/CD8 ratio with age, in the proportion of T cells that are Tregs, and in the proportion of CD4 and CD8 cells that are CD28+ and -. (C) Anti-CD3 + anti-CD28 stimulated proliferation (left panel) and IFNγ production (right panel). Results are expressed as the mean ± SEM. * indicates a statistically significant difference (P <0.05) between the young and old cohorts.

Journal: PLoS ONE

Article Title: Effect of age on chronic inflammation and responsiveness to bacterial and viral challenges

doi: 10.1371/journal.pone.0188881

Figure Lengend Snippet: (A) Differences in the proportions of monocytes, T cells and NK cells with age. (B) Differences with age in the % of T cells that are CD4+ and CD8+, in the CD4/CD8 ratio with age, in the proportion of T cells that are Tregs, and in the proportion of CD4 and CD8 cells that are CD28+ and -. (C) Anti-CD3 + anti-CD28 stimulated proliferation (left panel) and IFNγ production (right panel). Results are expressed as the mean ± SEM. * indicates a statistically significant difference (P <0.05) between the young and old cohorts.

Article Snippet: The antibodies used were: CD14-PE (clone MØp9), CD8-PE (clone SK1) and CD3-FITC (clone SK7) from StemCell Technologies, Vancouver, BC; CD45-FITC (Hle1), CD28-APC (clone CD28.2), CD4-PE-Cy7 (clone SK3), CD25-BB515 (clone 2A3), CD127-AF647 (clone HIL-7R-M21) and FoxP3-PE (clone 236A/E7) from BD Biosciences, Mississauga, ON; CD56-APC (clone CMSSB) from eBioscience, San Diego, CA.

Techniques: